GLP1R and type 2 diabetes mellitus: Adult people (≥ 18 years) with a diagnosis of obesity (body mass index ≥ 30 kg/m2) or T2DM (ICD-10-CM: E11) between 2018 and 2024 were subdivided in two mutually exclusive cohorts: (1) GLP-1 RA Users; and (2) Non–GLP-1 RA Users.